

# FHB welcomes latest work progress of measure of using HK registered drugs and medical devices used in HK public hospitals in Guangdong-Hong Kong-Macao Greater Bay Area

The Food and Health Bureau (FHB) welcomed today (April 17) the announcement made by the Guangdong Provincial Medical Products Administration (GDMPA) on the latest work progress of the measure of allowing designated healthcare institutions operating in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) to use Hong Kong-registered drugs with urgent clinical use, and medical devices used in Hong Kong public hospitals with urgent clinical use (the Measure), subject to the approval of Guangdong Province.

The Hong Kong Special Administrative Region Government has been maintaining close liaison with the relevant Mainland authorities to discuss the implementation of the Measure at the University of Hong Kong-Shenzhen Hospital (HKU-SZH) on a trial basis, including establishing a collaborative platform and making agreement on the directory of drugs and medical devices that can be used in designated healthcare institutions in the GBA etc. The GDMPA has commenced the Measure to use the relevant drugs and medical devices at the HKU-SZH on a trial basis, with a trial period up till July 31.

The Secretary for Food and Health, Professor Sophia Chan, said, "The HKSAR Government greatly welcomes the official implementation of the Measure, which can enable Hong Kong residents to seek suitable healthcare services in the GBA. I would also like to express gratitude to the People's Government of Guangdong Province for their staunch support. The HKSAR Government will continue to work and liaise closely with the GDMPA to implement the Measure, with a view to expanding the directory of drugs and medical devices as soon as possible, and extending the arrangement gradually to cover more designated healthcare institutions in the GBA after achieving phased progress under the trial arrangement at the HKU-SZH. We hope to provide greater medical convenience for Hong Kong residents working and living in the GBA, to foster mutual benefits, connectivity and in-depth integration of the medical and pharmaceutical industries in the GBA, as well as to improve the level of healthcare services in the Area."

Through the Measure, the first drug item, Anti-D (Rho) immunoglobulins injection, and the first medical device, Magnetically Controlled Growing Rods, have already been delivered to the HKU-SZH yesterday for clinical use. Anti-D (Rho) immunoglobulins injection can be used to prevent hemolysis of the newborn when RhD-negative women get pregnant again, while Magnetically Controlled Growing Rods can be used to correct severe spinal deformities in children. In addition, HKU-SZH's applications for new imported drugs for

treating lung cancer, lymphoma and severe chronic obstructive lung have also been approved.

The Central Government has promulgated the Work Plan for Regulatory Innovation and Development of Pharmaceutical and Medical Device in the Guangdong-Hong Kong-Macao Greater Bay Area on the website of the National Medical Products Administration on November 25, 2020, permitting designated Hong Kong-owned healthcare institutions operating in the GBA to use Hong Kong-registered drugs, and medical devices used in Hong Kong public hospitals with urgent clinical use and advanced clinical applications.